DAFTAR PUSTAKA

1. National Heart, Lung, and Blood Institute. U.S. National Library of Medicine. Coronary Artery Disease. Available from: https://medlineplus.gov/coronaryarterydisease.html
2. Nigam PK. Serum Lipid Profile Fasting or Non-fasting 2011;*26*(1): 96–97: Available from: https://www.ncbi.nlm.nih.gov/pubmed/22211025
3. Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison's Principles of Internal Medicine. 19th ed. McGraw-Hill Education. 2015.
4. Boudi FB, Ahsan CH. *Atherosclerosis: eMedicine Cardiology* 2009; 1-7. Available from: https://emedicine.medscape.com/article/153647-overview
5. Kementerian Kesehatan. Badan Penelitian dan Pengembangan Kesehatan. Hasil Utama Riskesdas 2018. Available from: http://www.depkes.go.id/resources/download/info-terkini/hasil-riskesdas-2018.pdf
6. Paoletti R, Bolego C, Poli A, Cignarella A. Metabolic Syndrome , Inflammation and Atherosclerosis. 2006;*2*(2), 145–152. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1993992/
7. Kementerian Kesehatan RI. Riset Kesehatan Dasar. Indonesia: The Institute;2013.
8. American Heart Association. Prevention and Treatment of High Cholesterol (Hyperlipidemia). (updated 2017 Apr 30, cited 2018 nov 15). Available from: http://www.heart.org/en/health-topics/cholesterol/hdl-good-ldl-bad-cholesterol-and-triglycerides.
9. Indonesian Heart Association. Pedoman Tatalaksana Dislipidemia. Indonesia: Centra Communications;2013.
10. Kashani H, Zeraati H, Mohammad K, Goodarzynejad H, Mahmoudi M, Sadeghian S, Boroumand M. Analyzing gensini score as a semi-continuous outcome. *Journal of Tehran University Heart Center*. 2016;11(2), 55–61.
11. Zemel PC, Sowers JR. Relation between lipids and atherosclerosis: Epidemiologie evidence and clinical implications. *The American Journal of Cardiology*. 1990;*66*(21), 7–12. Available from: https://www.ajconline.org/article/0002-9149(90)91257-7/pdf
12. Chan DC, Barrett HPR, Watts GF. Dyslipidemia in visceral obesity: Mechanisms, implications, and therapy. *American Journal of Cardiovascular Drugs*. 2004;*4*(4), 227–246. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15285698
13. National Heart, Lung, and Blood Institute. U.S. National Library of Medicine. Atherosclerosis. Available from: *https://www.nhlbi.nih.gov/health-topics/atherosclerosis*
14. Lily LS. Pathophysiology of Heart Disease. 5th ed. Wolters Kluwer. 2011:113-134.
15. Rafieian-kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis : Process , Indicators , Risk Factors and New Hopes. 2014; *5*(8), 927–946. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4258672/

16. Eren E, Yilmaz N, Aydin O. Functionally defective high-density lipoprotein and paraoxonase; a couple for endothelial dysfunction in atherosclerosis. Cholesterol. 2013; 2013:792090.
17. Yan Y, Chang Q, Li Q, Li L, Wang S, Du R, et al. Identification of plasma vascular endothelia-cadherin as a biomarker for coronary artery disease in type 2 diabetes melitus patients. Int J Clin Exp Med. 2015; 8(!)): 19466-19470.
18. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms; the Kelly West Award Lecture 2008. Diabetes Care. 2010; 333(2): 442-449.
19. Jax Tw, Peters AJ, Plehn G, Schoebel FC, Hemostatic risk factors in patients with coronary artery disease and type 2 diabetes – a two year follow-up of 243 patients, Cardiovase Diabetol. 2009; 8-48.
20. Linton MF, Yancey PG, Jerome WGJ. The Role of Lipids and Lipoproteins in Atherosclerosis Atherosclerosis in Cardiovascular Disease. 2015. Available from: https://www.ncbi.nlm.nih.gov/books/NBK343489/
21. Bosomworth, N. J. Practical use of the Framingham risk score in primary prevention: Canadian perspective. *Canadian Family Physician*. 2011;*57*(4), 417–423.
22. Montorsi, Piero & M Ravagnani, Paolo & Galli, Stefano & Rotatori, Francesco & Veglia, Fabrizio & Briganti, et al. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: The COBRA trial. European heart journal. 2006;27.
23. Lewis SJ. Prevention and Treatment of Atherosclerosis: A Practitioner's Guide for 2008. Am J Med. 2009;122:S38-S50.
24. Schwartz AL. Physical Activity. *Seminars in Oncology Nursing*. 2008;*24*(3), 164–170. Available from: https://www.nhlbi.nih.gov/node/24059
25. Nagoshi R, Okamura T, Murasato Y, Fujimura T, Yamawaki M, et al. Data on two- and three- dimensional optical coherence tomography guidance for the treatment for the bifurcation lesion. Elsevier. *Data in Brief*. 2018;*16*, 865–868. Available from: https://doi.org/10.1016/j.dib.2017.12.024
26. National Heart, Lung, and Blood Institute. U.S. National Library of Medicine. Coronary Artery Bypass Grafting. Available from: *https://www.nhlbi.nih.gov/health-topics/coronary-artery-bypass-grafting*
27. Sardar P, Chatterjee S, Aronow HD, Kundu A, Ramchand P, Mukherjee D, et al. Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention. Journal of the American College of Cardiology. 2017;*69*(18). Available from: https://doi.org/10.1016/j.jacc.2017.02.053
28. Ford MA, Allison TG, Lerman A. New approach to the concept of primary prevention of atherosclerosis. Current Treatment Option in Cardiovascular Medicine. 2008;10:73-82.
29. Napoli C, Lerman LO, Nigris F, Gossl M, Balestrieri ML, Lerman A. Rethinking Primary Prevention of Atherosclerosis-Related Disease. Circulation. 2006;114:2517-2527.
30. Musunuru K. Atherogenic Dyslipidemia: Cardiovascular Risk and Dietary Intervention. Lipid 2010;45:907-914.
31. R Ma'rufi, L Rosita. Hubungan dislipidemia dan kejadian Penyakit Arteri Koroner. 2014; *6*(1), 1–7.

32. Moran AE, Forouzanfar MH, Roth GA, Mensah GA, Ezzati M, Flaxman A, Murray CJ, Naghavi M. The global burden of ischemic heart disease in 1990 and 2010: the Global Burden of Disease 2010 study. *Circulation*. 2014;129:1493–1501.
33. Kumar S, Verma AK, Kumar N, Verma RK, Kumar N. Prevalence of Coronary Atherosclerosis in Different Age Groups : A Postmortem, 2013;*24*(1), 50–53.
34. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF. Lovelock CE, et al. Population- based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). *Lancet*. 2005;366:1773–1783. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16298214
35. Rodríguez-saldaña J, Rodriguez-flores M, Cantú-brito C, Aguirre-garcia JA. Pathological Study of the Epidemiology of Atherosclerosis in Mexico City. 2014.
36. Wongkar AH, Kandou GD, Rattu AJM. Hubungan Profil Lipid Darah *Low Density Lipoprotein* dengan Kejadian Penyakit Arteri Koroner di BLU RSUP. Prof. DR. R.D. Kandou Manado. 2014. Available from: https://ejournalhealth.com/index.php/t2/article/view/147/143
37. Su C, Chen K, Sheu WH, Yang Y, Liu T, Chang W, et al. Lack of Association between High-Density Lipoprotein Cholesterol and Angiographic Coronary Lesion Severity in Chinese Patients with Low Background Low-Density Lipoprotein Cholesterol. 2015;528–535. Available from: https://doi.org/10.6515/ACS20150421A
38. Sudjana PA, Achmad C, Yahya AF, Januar W, Akbar MR. Correlation between Triglyceride / HDL Ratio with Severity of Coronary Artery Lesion in Non-Diabetic Stable Angina Pectoris Patients. 2018;*4*(2), 95–102.
39. Farahdika A, Mahalul A. Faktor Risiko yang Berhubungan dengan Penyakit Arteri Koroner pada Usia Dewasa Madya (41 – 60 tahun). Unnes Journal of Public Health. 2015;*4*(2), 117–123.
40. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic , epidemiologic , and clinical studies . A consensus statement from the European Atherosclerosis Society Consensus Panel. 2017;*38*(32), 2459–2472.
41. Zalukhu Y, Purnamaningsih SM, Taufik Nahar, Suwarso S. Small Dense Low Density Lipoprotein with Angiographically Atherosclerosis In Coronary Heart Disease. Clinical Pathology and Medical Laboratory. 2016; *22*(3).
42. Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Disease. Oxidative Medicine and Cellular Longevity. 2017. ID 1273042. Available from: https://www.hindawi.com/journals/omcl/2017/1273042/